 Connection
Eric Wu to Female
This is a "connection" page, showing publications Eric Wu has written about Female.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.681 |
|
|
|
-
Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020 08; 36(8):1333-1341.
Score: 0.028
-
Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ. The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis. J Manag Care Spec Pharm. 2019 Dec; 25(12):1398-1408.
Score: 0.027
-
Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018 06; 34(6):971-978.
Score: 0.024
-
Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2017 Sep; 26(9):1996-2003.
Score: 0.023
-
Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ. A Risk Score for Fluconazole Failure among Patients with Candidemia. Antimicrob Agents Chemother. 2017 05; 61(5).
Score: 0.023
-
Gu?rin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother. 2016 Jun; 17(9):1189-96.
Score: 0.021
-
Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. Clin Ther. 2016 05; 38(5):1205-16.
Score: 0.021
-
Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites. Clin Ther. 2016 04; 38(4):905-17.
Score: 0.021
-
Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a?physician survey. Cancer Med. 2016 Feb; 5(2):209-20.
Score: 0.021
-
Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. Expert Opin Pharmacother. 2015; 16(14):2101-11.
Score: 0.020
-
Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin. 2015 Aug; 31(8):1573-82.
Score: 0.020
-
Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clin Ther. 2015 Aug; 37(8):1713-25.e3.
Score: 0.020
-
Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ. Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. J Manag Care Spec Pharm. 2015 Apr; 21(4):308-18.
Score: 0.020
-
Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health. 2015 Mar; 18(2):198-205.
Score: 0.020
-
Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China. Pharmacoeconomics. 2014 Mar; 32(3):305-13.
Score: 0.018
-
Wu EQ, Forsythe A, Gu?rin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012 Nov; 19(6):e157-66.
Score: 0.017
-
Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012 Sep-Oct; 15(6):940-7.
Score: 0.017
-
Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ. 2012; 15(6):1078-87.
Score: 0.016
-
Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. J Med Econ. 2012; 15(4):786-95.
Score: 0.016
-
Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012 Jan; 124(1):124-32.
Score: 0.016
-
Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):326-35.
Score: 0.015
-
Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother. 2011 Apr; 45(4):441-51.
Score: 0.015
-
Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. Am J Cardiovasc Drugs. 2011; 11(1):21-32.
Score: 0.015
-
Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ. 2009 Jun; 12(2):124-35.
Score: 0.013
-
Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009 May; 36(5):1032-40.
Score: 0.013
-
Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008 Dec; 24(12):3493-501.
Score: 0.013
-
Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006 Nov; 36(11):1535-40.
Score: 0.011
-
Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H. Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population. Pharmacoeconomics. 2006; 24(1):55-65.
Score: 0.010
-
Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005 Sep; 66(9):1122-9.
Score: 0.010
-
Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005 Oct 15; 58(8):668-76.
Score: 0.010
-
Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005 May; 47(5):439-46.
Score: 0.010
-
Stein EM, Bonifacio G, Latr?mouille-Viau D, Shi S, Gu?rin A, Wu EQ, Sadek I, Cao X. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. J Med Econ. 2021 Jan-Dec; 24(1):234-243.
Score: 0.007
-
Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. J Manag Care Spec Pharm. 2017 Jul; 23(7):771-780.
Score: 0.006
-
Soliman AM, Du EX, Yang H, Wu EQ, Haley JC. Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy. J Womens Health (Larchmt). 2017 06; 26(6):644-654.
Score: 0.006
-
Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Adv Ther. 2017 01; 34(1):207-220.
Score: 0.006
-
Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Gu?rin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97.
Score: 0.005
-
Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Gu?rin A. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Curr Med Res Opin. 2016; 32(2):385-94.
Score: 0.005
-
Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Gu?rin A. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. J Med Econ. 2016; 19(4):414-23.
Score: 0.005
-
Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Dec 29; 15:167.
Score: 0.005
-
Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respir Med. 2015 Dec; 109(12):1582-8.
Score: 0.005
-
Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer. J Comp Eff Res. 2015 Aug; 4(4):315-26.
Score: 0.005
-
Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin. 2015 Jun; 31(6):1095-103.
Score: 0.005
-
Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. Fertil Steril. 2015 Jan; 103(1):163-71.
Score: 0.005
-
Mody R, Gu?rin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Prevalence and risk of developing comorbid conditions in patients with chronic constipation. Curr Med Res Opin. 2014 Dec; 30(12):2505-13.
Score: 0.005
-
Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ. 2013; 16(2):278-88.
Score: 0.004
-
Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2013; 16(2):260-2.
Score: 0.004
-
Yu AP, Gu?rin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011 Dec; 105(12):1861-71.
Score: 0.004
-
Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ. 2011; 14(5):542-52.
Score: 0.004
-
Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011; 14(3):315-23.
Score: 0.004
-
Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP. Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ. 2011; 14(3):267-78.
Score: 0.004
-
Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011 Feb 01; 12(1):51-62.
Score: 0.004
-
Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M. Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. J Med Econ. 2010; 13(4):599-609.
Score: 0.004
-
Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010 Sep; 26(9):2065-76.
Score: 0.004
-
Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2009 Nov; 21(11):1302-9.
Score: 0.003
-
Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9.
Score: 0.003
-
Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
Score: 0.003
-
Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9.
Score: 0.003
-
Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation. 2008 Jul 29; 118(5):491-7.
Score: 0.003
-
Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health. 2007 Nov-Dec; 10(6):443-50.
Score: 0.003
-
Colice G, Wu EQ, Birnbaum H, Daher M, Maryna M. Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma. 2007 Jul-Aug; 44(6):479-83.
Score: 0.003
-
Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring). 2007 Feb; 15(2):511-21.
Score: 0.003
-
Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006 Oct; 37(10):2567-72.
Score: 0.003
-
Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006 Aug; 48(8):794-802.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|